Toni K. Choueiri, MD
Copenhagen, Denmark—In first-line treatment of poor- or intermediate-risk metastatic renal cell carcinoma (mRCC), cabozantinib results in a substantially longer progression-free survival (PFS) than sunitinib, according to a randomized, multicenter, Phase II trial. The increased PFS was consistent with a substantially greater objective response rate (ORR).
On the basis of these results, which were presented at the European Society for Medical Oncology (ESMO) 2016